Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2025; 15(2): 127-141


Development and evaluation of remdesivir dry powder inhalation formulation by spray drying technique

Mukesh Pandurang Ratnaparkhi, Gajanan Madhukar Kulkarni, Shailendra S. Salvankar, Avinash Ramrao Tekade.




Abstract

Remdesivir is an antiviral drug that has broad activity against members of the filovirus, Coronaviruses, and paramyxovirus. After oral administration, it is highly metabolized in the liver resulting in low bioavailability. On the other hand, parenteral administration has systemic side effects. Therefore, in this study, an effort has been undertaken to develop the remdesivir mucoadhesive dry powder inhalation (DPI) formulation by spray drying technique targeting the lung for immediate onset of action and to reduce the side effects of remdesivir associated with parenteral administration. The feed solution was prepared by dissolving a sufficient amount of the drug with Lactose, Leucine, B-cyclodextrin, and a novel mucoadhesive agent (Samanea saman seed gum) at different concentrations in a solvent system of ethanol: water (50:50 v/v) with the help of sonication. After that spray drying process was performed employing a spray dryer. All DPI formulations showed a geometrical size ranging from 3 to 4.8 μm and a polydispersity index less than 0.5. The raw remdesivir showed rectangular-shaped particles, whereas the optimized DPI formulation showed irregular morphology with a rough exterior. Differential scanning calorimetry (DSC) and X-ray powder diffraction study illustrated that the spray drying process changed the crystallinity of the drug as well as other excipients by converting them into the amorphous form. Thereby, increasing the solubility of remdesivir in DPI formulations by about 15–18 times higher than that of plain remdesivir. The amorphous form likely dissolves more quickly than the crystalline form due to stronger intermolecular forces in the crystal and its higher free energy. The drug content and drug release (at the end of 5 hours in phosphate buffer solution (PBS) with a constant temperature of 37°C ± 1°C) were found to be 89.73% ± 2.17% and 79.4% ± 2.2%, respectively. The optimal DPI formulation exhibited excellent aerodynamic performance with 43.583% fine particle fraction and 2.13 μm mass median aerodynamic diameter. Formulated DPI represented a promising strategy for administering remdesivir via the pulmonary route for localized action against pulmonary viral infections.

Key words: Dry Powder Inhalation, mucoadhesion, pulmonary drug delivery, remdesivir, respiratory viruses, spray drying






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.